Does Moderna support Israel?

Signed its initial COVID-19 vaccine supply agreement with Israel's Ministry of Health, announced by Prime Minister Netanyahu in June 2020 — one of Moderna's earliest international supply deals. Financial terms were not officially disclosed; Israeli media reports ranged from about $60 million for one million doses (CTech) to NIS 405 million (~$120 million, Times of Israel). Chief Medical Officer Tal Zaks later said "Israel was among the first countries we approached to offer the opportunity to purchase our Covid-19 vaccine early."

Amended the supply agreement with Israel's Ministry of Health to add doses, bringing Israel's confirmed order to 6 million doses of mRNA-1273. Moderna's FY2020 annual report lists Israel among its committed supply agreements at "Israel: 6 million doses."

Announced a new supply agreement with the Israeli government for 2022 — Moderna's first firm order for 2022 supply — including an option for variant-specific booster doses; the two earlier agreements had totaled 10 million doses. CEO Stéphane Bancel cited "the continued confidence and collaboration with the Israel Ministry of Health." Moderna's own announcement stated no dose figure for the new order; the Israeli press did, and disagreed — Globes reported 8 million doses to be delivered by the end of 2022, beside 10 million from Pfizer signed the same day, while Walla reported nine million and TheMarker about six million. Globes gave the price as $30 a dose and NIS 1.8 billion for the two companies' contracts together, paid out of surplus in the already-approved Covid-19 budget so that no fresh cabinet decision was needed, and reported a clause in the Moderna contract requiring Israel to use the vaccine widely in the population rather than hold it in reserve — a commercial condition on a sale, not support.

Partnered with Israel-based Medison Pharma to commercialize Moderna's COVID-19 vaccine across Central and Eastern Europe and Israel, a multi-country commercialization agreement covering about 20 markets. Medison, not Moderna, is the acting local partner in Israel.

Runs clinical development in Israel: its FY2020 10-K lists Israel among trial locations for the mRNA-2416 and mRNA-2752 intratumoral oncology studies ("sites in the United States and Israel") and among planned Phase 3 countries for its CMV vaccine candidate mRNA-1647. R&D activity, not donations or political support.